923274-85-5Relevant articles and documents
Synthesis and SAR of potent inhibitors of the Hepatitis C virus NS3/4A protease: Exploration of P2 quinazoline substituents
Nilsson, Magnus,Belfrage, Anna Karin,Lindstroem, Stefan,Waehling, Horst,Lindquist, Charlotta,Ayesa, Susana,Kahnberg, Pia,Pelcman, Mikael,Benkestock, Kurt,Agback, Tatiana,Vrang, Lotta,Terelius, Ylva,Wikstroem, Kristina,Hamelink, Elizabeth,Rydergard, Christina,Edlund, Michael,Eneroth, Anders,Raboisson, Pierre,Lin, Tse-I,de Kock, Herman,Wigerinck, Piet,Simmen, Kenneth,Samuelsson, Bertil,Rosenquist, Asa
scheme or table, p. 4004 - 4011 (2010/08/06)
Novel NS3/4A protease inhibitors comprising quinazoline derivatives as P2 substituent were synthesized. High potency inhibitors displaying advantageous PK properties have been obtained through the optimization of quinazoline P2 substituents in three series exhibiting macrocyclic P2 cyclopentane dicarboxylic acid and P2 proline urea motifs. For the quinazoline moiety it was found that 8-methyl substitution in the P2 cyclopentane dicarboxylic acid series improved on the metabolic stability in human liver microsomes. By comparison, the proline urea series displayed advantageous Caco-2 permeability over the cyclopentane series. Pharmacokinetic properties in vivo were assessed in rat on selected compounds, where excellent exposure and liver-to-plasma ratios were demonstrated for a member of the 14-membered quinazoline substituted P2 proline urea series.
PYRIMIDINE SUBSTITUTED MACROCYCLIC HCV INHIBITORS
-
, (2008/12/08)
Compounds of the Formula (I) including a stereoisomer thereof, or an N-oxide, a pharmaceutically acceptable addition salt, or a pharmaceutically acceptable addition solvate thereof; useful as HCV inhibitors; processes for preparing these compounds as well as pharmaceutical compositions comprising these compounds as active ingredient.
